Synchroneuron, a Waltham, MA-based biopharmaceutical company focused on developing new therapies to treat tardive dyskinesia (TD) and other neuropsychiatric disorders, closed a $20m Series B funding.
The round came from sole-investor Morningside Technology Ventures Limited.
The company intends to use the funds for the continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia (TD).
Founded in 2011 by inventor and neurologist Barry Fogel, William Kerns, DVM, Chief Executive Officer, Kei-Lai Fong, PhD, and Marc Cote, Synchroneuron is engaged in developing novel treatments to treat tardive dyskinesia (TD) and other neuropsychiatric disorders.
SNC-102 is a formulation of acamprosate calcium, an FDA-approved drug for treating alcohol dependence. The use of acamprosate calcium in the treatment of tardive dyskinesia (TD) was pioneered by Synchroneuron co-founder and inventor, Barry Fogel, MD, a neuropsychiatrist and behavioral neurologist at the Brigham and Women’s Hospital and Clinical Professor of Psychiatry at Harvard Medical School. SNC-102 was developed by Synchroneuron to improve the pharmacokinetic properties of acamprosate. Synchroneuron’s Phase 1 studies have shown that SNC-102 can produce sustained plasma levels of acamprosate that are anticipated to be efficacious for treating TD and potentially other neuropsychiatric disorders.
The company had secured $6m in Series A financing in 2012 from Morningside Technology Ventures (read here).